- Home
- SWIN vs NRXP Comparison
SWIN vs NRXP Comparison
Compare SWIN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- NRXP
- Stock Information
- Founded
- SWIN 2017
- NRXP 2015
- Country
- SWIN Hong Kong
- NRXP United States
- Employees
- SWIN N/A
- NRXP N/A
- Industry
- SWIN
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- NRXP Health Care
- Exchange
- SWIN Nasdaq
- NRXP Nasdaq
- Market Cap
- SWIN 32.1M
- NRXP 32.6M
- IPO Year
- SWIN 2023
- NRXP N/A
- Fundamental
- Price
- SWIN $3.71
- NRXP $3.05
- Analyst Decision
- SWIN
- NRXP Strong Buy
- Analyst Count
- SWIN 0
- NRXP 4
- Target Price
- SWIN N/A
- NRXP $28.50
- AVG Volume (30 Days)
- SWIN 283.9K
- NRXP 188.0K
- Earning Date
- SWIN 08-21-2025
- NRXP 08-13-2025
- Dividend Yield
- SWIN N/A
- NRXP N/A
- EPS Growth
- SWIN N/A
- NRXP N/A
- EPS
- SWIN N/A
- NRXP N/A
- Revenue
- SWIN $3,316,000.00
- NRXP N/A
- Revenue This Year
- SWIN $29.79
- NRXP N/A
- Revenue Next Year
- SWIN $54.60
- NRXP N/A
- P/E Ratio
- SWIN N/A
- NRXP N/A
- Revenue Growth
- SWIN N/A
- NRXP N/A
- 52 Week Low
- SWIN $1.16
- NRXP $1.10
- 52 Week High
- SWIN $4.40
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- SWIN 66.98
- NRXP 43.40
- Support Level
- SWIN $2.93
- NRXP $3.12
- Resistance Level
- SWIN $3.99
- NRXP $3.53
- Average True Range (ATR)
- SWIN 0.44
- NRXP 0.16
- MACD
- SWIN -0.01
- NRXP -0.07
- Stochastic Oscillator
- SWIN 72.37
- NRXP 3.92
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.